CVS Health Co. (NYSE:CVS) Shares Purchased by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. raised its holdings in CVS Health Co. (NYSE:CVSGet Rating) by 0.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 336,984 shares of the pharmacy operator’s stock after acquiring an additional 1,686 shares during the period. Candriam Luxembourg S.C.A.’s holdings in CVS Health were worth $34,764,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. West Bancorporation Inc. purchased a new position in CVS Health in the 4th quarter valued at about $25,000. Bell Investment Advisors Inc acquired a new stake in CVS Health in the 3rd quarter valued at about $26,000. Capital Advisors Ltd. LLC raised its holdings in CVS Health by 125.7% in the 4th quarter. Capital Advisors Ltd. LLC now owns 316 shares of the pharmacy operator’s stock valued at $33,000 after acquiring an additional 176 shares during the last quarter. Steph & Co. raised its holdings in CVS Health by 138.7% in the 4th quarter. Steph & Co. now owns 358 shares of the pharmacy operator’s stock valued at $37,000 after acquiring an additional 208 shares during the last quarter. Finally, Lowe Wealth Advisors LLC raised its holdings in CVS Health by 35.8% in the 4th quarter. Lowe Wealth Advisors LLC now owns 383 shares of the pharmacy operator’s stock valued at $39,000 after acquiring an additional 101 shares during the last quarter. 78.00% of the stock is currently owned by institutional investors and hedge funds.

In other news, EVP Daniel P. Finke sold 55,359 shares of CVS Health stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $100.13, for a total value of $5,543,096.67. Following the transaction, the executive vice president now owns 3,098 shares of the company’s stock, valued at $310,202.74. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Prem S. Shah sold 5,346 shares of the business’s stock in a transaction on Wednesday, March 30th. The stock was sold at an average price of $104.70, for a total transaction of $559,726.20. The disclosure for this sale can be found here. Insiders sold a total of 82,283 shares of company stock worth $8,376,142 in the last ninety days. Corporate insiders own 0.69% of the company’s stock.

NYSE CVS traded down $0.44 during trading hours on Tuesday, reaching $98.11. 18,661 shares of the company traded hands, compared to its average volume of 5,720,501. CVS Health Co. has a 12 month low of $79.33 and a 12 month high of $111.25. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $128.65 billion, a PE ratio of 16.37, a PEG ratio of 1.54 and a beta of 0.78. The company has a 50 day moving average of $102.89 and a two-hundred day moving average of $101.24.

CVS Health (NYSE:CVSGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The pharmacy operator reported $2.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.08. CVS Health had a net margin of 2.67% and a return on equity of 15.33%. The company had revenue of $76.83 billion for the quarter, compared to the consensus estimate of $75.30 billion. During the same period last year, the firm posted $2.04 EPS. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. On average, equities research analysts anticipate that CVS Health Co. will post 8.32 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 2nd. Stockholders of record on Friday, April 22nd were paid a $0.55 dividend. The ex-dividend date was Thursday, April 21st. This represents a $2.20 annualized dividend and a dividend yield of 2.24%. CVS Health’s dividend payout ratio is currently 36.54%.

A number of analysts have recently issued reports on CVS shares. Deutsche Bank Aktiengesellschaft raised their price target on shares of CVS Health from $110.00 to $113.00 in a report on Thursday, May 5th. StockNews.com started coverage on shares of CVS Health in a report on Thursday, March 31st. They set a “strong-buy” rating for the company. BMO Capital Markets raised their price target on shares of CVS Health from $108.00 to $120.00 in a report on Thursday, February 10th. Raymond James downgraded shares of CVS Health from a “strong-buy” rating to an “outperform” rating and raised their price target for the stock from $115.00 to $120.00 in a report on Friday, February 11th. Finally, Tigress Financial raised their price target on shares of CVS Health from $122.00 to $125.00 in a report on Thursday, April 7th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $114.90.

CVS Health Company Profile (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Read More

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSGet Rating).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.